FDA grants cardiotrophin-1 Orphan Drug status for acute liver failure treatment to Digna Biotech
Digna Biotech receives FDA approval for cardiotrophin-1 as an acute liver failure treatment. The medicine is expected to work by acting as a messenger to damaged liver cells, helping them recover and restoring function. Cardiotrophin-1 has been shown to stimulate hepatic regeneration and protect hepatocytes during acute hepatic damage.